drugset
drugset / Trial / NCT04908995

Safety, Tolerability, Pharmacokinetics and Food Effects of Oral EC5026 in Healthy Subjects

NCT04908995 ↗

Phase 1 Completed 18 enrolled EicOsis Human Health Inc.
RandomizedParallel-groupDouble-blindOther

Summary

The purpose of the study is to provide safety, tolerability, pharmacokinetics and food effects data of a single 8 mg oral dose of EC5026 in healthy subjects.

Timeline

Start
2021-04-30
Primary completion
2021-05-12
Completion
2021-11-24

Drugs

EvaluationDrugModalityDoseRoute
Subject EC5026 Unknown 8 mg Oral

Indications

No indication recorded.